Impact of transpulmonary thermodilution-based cardiac contractility and extravascular lung water measurements on clinical outcome of patients with Takotsubo cardiomyopathy after subarachnoid hemorrhage: a retrospective observational study by Tatsushi Mutoh et al.
Mutoh et al. Critical Care 2014, 18:482
http://ccforum.com/content/18/4/482RESEARCH Open AccessImpact of transpulmonary thermodilution-based
cardiac contractility and extravascular lung water
measurements on clinical outcome of patients
with Takotsubo cardiomyopathy after
subarachnoid hemorrhage: a retrospective
observational study
Tatsushi Mutoh1,2*, Ken Kazumata3,4, Shunsuke Terasaka3, Yasuyuki Taki2, Akifumi Suzuki1 and Tatsuya Ishikawa1Abstract
Introduction: Takotsubo cardiomyopathy (TCM) is a life-threatening systemic consequence early after subarachnoid
hemorrhage (SAH), but precise hemodynamics and related outcomes have not been studied. The purpose of this
study was to investigate TCM-induced cardiac function by transpulmonary thermodilution and its impact on clinical
outcome of SAH.
Methods: We retrospectively analyzed 46 consecutive postoperative SAH patients who developed TCM. Patients
were divided into two groups of echocardiographic left ventricular ejection fraction (LVEF) <40% (TCM with left
ventricular (LV) dysfunction) and LVEF ≥40% (TCM without LV dysfunction). Cardiac function index (CFI) and
extravascular lung water index (ELWI) were monitored by transpulmonary thermodilution in parallel with serial
measurements of echocardiographic parameters and blood biochemical markers.
Results: Transpulmonary thermodilution-derived CFI was significantly correlated with LVEF (r = 0.82, P < 0.0001). The
CFI between days 0 and 7 was significantly lower in patients with LV dysfunction (LVEF <40%) than in patients with
LVEF ≥40% (P < 0.05). CFI had a better ability than cardiac output to detect cardiac dysfunction (LVEF <40%) (area
under the curve = 0.85 ± 0.02; P < 0.001). A CFI value <4.2 min−1 had a sensitivity of 82% and specificity of 84% for
detecting LVEF <40%. CFI <4.2 min−1 was associated with delayed cerebral ischemia (DCI) (odds ratio (OR) = 2.14,
95% confidence interval (CI) = 1.33 to 2.86; P = 0.004) and poor 3-month functional outcome on a modified Rankin
Scale of 4 to 6 (OR = 1.87, 95% CI = 1.06 to 3.29; P = 0.02). An extravascular lung water index (ELWI) >14 ml/kg after day
4 increased the risk of poor functional outcome at 3-month follow-up (OR = 2.10, 95% CI = 1.11 to 3.97; P = 0.04).
Conclusions: Prolonged cardiac dysfunction and pulmonary edema increased the risk of DCI and poor 3-month
functional outcome in postoperative SAH patients with TCM. Serial measurements of CFI and ELWI by transpulmonary
thermodilution may provide an easy bedside method of detecting early changes in cardiopulmonary function to direct
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Autonomic storm after aneurysmal subarachnoid hemo-
rrhage (SAH) can adversely affect cardiovascular parame-
ters and may result in stress-related cardiomyopathy [1].
One distinct morphological variant of this phenomenon is
apical ballooning syndrome, known as Takotsubo cardio-
myopathy (TCM), which is characterized by hypokinesis
of the basal and middle portions of the left ventricle [2].
Although TCM may be reversible or self-limiting, it
contributes significantly to morbidity and mortality after
SAH, especially when it is combined with other neuro-
genic injuries, such as flash pulmonary edema and car-
diogenic shock [3]. Furthermore, left ventricular (LV)
dysfunction associated with TCM combined with cerebral
vasospasm may increase the risk of delayed cerebral ische-
mia (DCI) [4,5], and thus it may impact clinical outcome
[6]. However, the hemodynamic changes associated with
post-SAH TCM are currently poorly understood, presum-
ably because of the complicated underlying acute patho-
physiological mechanisms.
Cardiovascular monitoring is essential for the diagnos-
tic and therapeutic management of critically ill patients
and for assessing LV systolic function. Echocardiography
is currently the most frequently used imaging modality
for bedside assessment of LVEF [7,8], but it is not ideal
for real-time monitoring of systolic function because of
its high intra- and interobserver variability [9]. Monitor-
ing by transpulmonary thermodilution incorporated into
the PiCCO™ monitor (PULSION Medical Systems, Mun-
ich, Germany) provides continuous cardiac output (CO)
measurements derived from beat-to-beat pulse contour
analysis and intermittent estimations of global end-diastolic
volume (GEDV) and extravascular lung water (EVLW)
[10]. Furthermore, the data can be used to calculate the
cardiac function index (CFI), which is the ratio of CO to
GEDV [11]. Pilot data suggest that CFI is closely related to
the LV fractional area of change measured by echocardiog-
raphy [12,13] and that CFI can be used to accurately assess
the effects of positive inotropic therapy with dobutamine in
acute circulatory failure [7]. We hypothesized that CFI
could be used as a marker of LV systolic function to track
the acute hemodynamic changes of post-SAH TCM.
The aims of this study were (1) to investigate the
changes in cardiac function in postoperative SAH patients
with TCM by transpulmonary thermodilution, and then
(2) to test whether CFI and EVLW could predict outcome




In this retrospective analysis of a prospectively collected
data set, we considered all patients enrolled in our
cohort trials (Information Network Clinical Trials RegistryUMIN000007509) between April 2005 and March 2013.
This study was approved by the institutional review boards
of the two participating stroke centers (Teine Keijinkai
Hospital Institutional Review Board and Office of Research
Administration at the Research Institute for Brain and
Blood Vessels-Akita). According to the informed consent
guidelines in Japan [16], it is unnecessary to obtain infor-
med consent from each patient or person responsible to
use secondary data from the previous database; therefore,
this requirement for written informed consent was waived.
Clinical, hemodynamic and radiological data of all SAH
patients diagnosed with TCM and monitored with the
PiCCO™ device were collected retrospectively.
Transthoracic echocardiography
Transthoracic echocardiography was performed for all
patients immediately after admission to the emergency
department and was repeated simultaneously with CFI
measurements using the PiCCO™ device at least more
than once daily until day 14. LV ejection fraction (LVEF)
was measured using the Simpson method (basically ac-
quired using the biplane method, but a single-plane ap-
proach was used when the biplane method was technically
inadequate). The echocardiographic criteria for a diagnosis
of TCM included the presence of severe regional wall
motion abnormalities, mostly affecting the apical and mid-
ventricular segments [4,17].
PiCCO™-guided fluid management
Patients were managed according to previously described
SAH treatment protocols (see Additional file 1) [18-21].
For hemodynamic monitoring, thermistor-tipped arterial
PiCCO™ catheter (4-French, 16-cm, PV2014L16, Pulsiocath;
PULSION Medical Systems) was inserted into the femoral
artery and connected to the PiCCO™plus monitor (version
6.0; PULSION Medical Systems) for determination of CO,
GEDV, CFI and EVLW in the ICU immediately after sur-
gery. CO, GEDV and EVLW were indexed for body surface
area to obtain CI, GEDI and ELWI, respectively. Full details
of the PiCCO™ measurements are described elsewhere (see
Additional file 1).
Hemodynamic stability was defined as CI ≥3.0 L/min/m2,
GEDI ≥680 ml/m2 and ELWI ≤14 ml/kg. The upper limits
chosen were the values associated with a higher risk of
mortality in patients with pulmonary edema [22,23]. Hypo-
volemia (GEDI <680 ml/m2) was corrected by increasing
daily intravenous fluids (or intermittent fluid infusion, as
needed). Low CI associated with TCM was treated with
milrinone (0.125 to 0.5 μg/kg/min, maximum) or dobuta-
mine (3 to 9 μg/kg/min) to maintain CI ≥3.0 L/min/m2
[24]. Elevated ELWI (>14 ml/kg) with any signs of con-
gestive heart failure or pulmonary edema (such as bilateral
pulmonary infiltrates or cardiomegaly with a cardiothor-
acic ratio >50% on chest radiography) was treated with
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bolus) by carefully monitoring GEDI to avoid hypovolemia.
Clinical deterioration due to DCI or evidence of
cerebral vasospasm on transcranial Doppler ultrasono-
gram (mean flow velocity in the middle cerebral ar-
tery >120 cm/s) was treated initially with volume
expansion with 500 ml of 6% hydroxyethyl starch (10 ml/
kg/hr, one to three times per day);if this treatment was in-
effective, it was followed by hyperdynamic therapy with
incremental doses of dobutamine (3 μg/kg/min, max-
imum of 15 μg/kg/min) or milrinone (0.125 μg/kg/min,
maximum of 0.75 μg/kg/min) to raise the CI above the
normal limit (>5.0 L/min/m2) until the resolution of
symptoms [25,26].
Measurements
The following parameters were measured at least twice
daily during the study period (days 0 to 14 after the
onset of SAH): CI (manufacturer’s reference range = 3 to
5 L/min/m2); GEDI (680 to 800 ml/m2); ELWI (3 to
7 ml/kg); CFI (4.5 to 6.5 min−1); and plasma levels of
cardiac troponin I (0 to 0.5 ng/ml), adrenaline (0 to
0.1 ng/ml), noradrenaline (0.1 to 0.5 ng/ml) and brain
natriuretic peptide (0 to 18.4 mg/dl). Heart rate (HR),
mean arterial blood pressure (MAP), central venous pres-
sure (CVP) and systemic vascular resistance index (SVRI)
(1,700 to 2,400 dyn · s/cm5/m2) were simultaneously re-
corded. Measurements of transthoracic echocardiographic
parameters and plasma biochemical markers were perfor-
med simultaneously with the PiCCO™ measurements at
least once daily.
The primary parameter of interest was LV dysfunction
(LVEF <40%, defined as mildly reduced LV systolic func-
tion where inotropic support should be considered)
[14,27] between 4 and 14 days after the onset of SAH. In
this study, the SAH patients were divided into two
groups: LVEF <40% (TCM with LV dysfunction) and
LVEF ≥40% (TCM without LV dysfunction).
DCI was defined as a new focal neurological deficit or
global neurological deterioration (a decrease of two or
more points on the Glasgow Coma Scale) lasting longer
than 2 hours, after exclusion of intracranial hemorrhage,
hydrocephalus, seizures, metabolic derangements and
infection, with or without radiological signs of cerebral
vasospasm [28]. In unconscious patients, DCI was diag-
nosed when there was a lack of neurological progress in
the absence of the confounders described above or other
causes of brain damage observed on imaging examina-
tions, and if there was evidence of one of the following:
cerebral vasospasm evident on transcranial Doppler
ultrasound, magnetic resonance angiogram or digital sub-
traction angiogram; perfusion deficit on single-photon
emission computed tomogram; regional cerebral hypoxia
on near-infrared spectroscopy imaging scan; or cerebralinfarction on an imaging study not attributable to other
causes [25,29].
Functional outcome was assessed with the mRS at
3 months, divided into either poor outcome (score of 4
to 6) or favorable outcome (score of 0 to 3) [14,27]. We
also recorded the following data: (1) occurrence of car-
diopulmonary complications at presentation; (2) number
of patients treated with hyperdynamic therapy and the
clinical response (a positive response defined as at least
a one-point increase in the Glasgow Coma Scale score
from the worst score during the therapy, and a negative
response recorded if the patient was refractory to max-
imal dose infusion); (3) newly diagnosed or worsening
pulmonary edema after initiation of postoperative fluid
therapy (day 0 to day 14), defined as ELWI >14 ml/kg
based on the PiCCO™ measurements [22,23]; (4) pres-
ence of pulmonary edema after day 4 (that is, during
DCI risk period); (5) daily fluid intake/output and balance;
and (6) length of ICU stay.
We also considered those variables available at the
time of admission: age, sex, comorbid conditions, World
Federation of Neurosurgical Surgeons (WFNS) grade,
modified Fisher grade and cardiopulmonary complica-
tions (for example, pulmonary edema, arrhythmia and
hypotension).
Statistical analysis
Data are expressed as the mean (standard deviation) or
median (interquartile range), unless otherwise indicated.
Continuous data were compared using mixed-effects
analysis of variance (ANOVA; for groups and subjects
over time) with the post hoc Bonferroni–Dunn correc-
tion, as appropriate. Univariate analyses of the relation-
ships of categorical variables with outcomes of interest
were assessed using a χ2 test or Fisher’s exact test. Uni-
variate analyses of the relationships of normally distrib-
uted variables with outcomes of interest were assessed
using Student’s t-test, and of nonnormally distributed
variables were assessed using the Mann–Whitney U test.
The variables showing significant associations with DCI
and poor functional outcome on univariate analyses
were entered into a multivariate logistic regression
analysis. To determine the correlation between CFI
and echocardiographic LVEF over time (day after SAH
onset), a mixed-effects regression model was used. The
ability of CFI to predict LVEF <40% was determined by
receiver operating characteristic (ROC) curve analysis.
The area under the curve (AUC) was calculated based on
the ROC curves and expressed as a 95% confidence inter-
val. AUC ranges from 0.5 to 1.0. An AUC closer to 1
indicates a higher predictive power. All analyses were per-
formed using JMP Pro 11.0.0 software (SAS Institute,
Cary, NC, USA). P-values <0.05 were considered statisti-
cally significant.
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Patient characteristics
Forty-six (8%) of the five hundred seventy-five screened
patients were diagnosed with TCM. Their baseline
characteristics are shown in Table 1. Patients with LV
dysfunction (LVEF <40%) had a higher frequency of
WFNS grade IV or V (85% versus 50%; P = 0.014) and
a higher frequency of pulmonary edema (15% versus 50%;
P = 0.014) at presentation than those with LVEF ≥40%.
There were no significant differences between the two
groups for other baseline parameters, including age,
sex, modified Fisher grade based on computed tomo-
graphic scan, aneurysm location, treatment modality and
hypotension.
Comparison of cardiac function in patients with versus
without left ventricular dysfunction
A total of 1,330 PiCCO™ measurements were performed
over a mean period of 14 ± 1 days in the 46 SAH pa-
tients with TCM. At presentation, patients in bothTable 1 Baseline clinical characteristics of subarachnoid hemo
dysfunction following Takotsubo cardiomyopathya
Variable LVEF ≥40% (n = 26)
Age, yr 67 (55 to 75)
Sex, females/males 18/8
WFNS grade
I to III 13 (50%)
IV or V 13 (50%)





Anterior circulation 14 (54%)





Cardiac troponin T, ng/ml 0.6 (0.05 to 0.98)
Adrenaline, ng/ml 0.10 (0.03 to 0.14)
Noradrenaline, ng/ml 0.67 (0.26 to 1.15)
Brain natriuretic peptide, pg/ml 82 (32 to 130)
LVEF, % 44 (40 to 48)
Cardiopulmonary complication
Hypotension <90 mmHg 2 (8%)
Pulmonary edema 4 (15%)
aCT: Computed tomography; LVEF: Left ventricular ejection fraction; WFNS: World F
median (interquartile range). Categorical variables are expressed as counts (percent
Student’s t-test. Categorical variables were analyzed by χ2 test or Fisher’s exact test.groups (LVEF <40% and ≥40%) had low CFI (Figure 1A),
mainly attributable to decreased CI (Figure 1B) induced
by TCM. Low MAP (see Additional file 2) may also have
been associated with the TCM-induced CI depression.
The transpulmonary thermodilution-based hypovol-
emia (634 ± 57 ml/m2 versus 698 ± 70 ml/m2; P = 0.03)
(Figure 1C) and pulmonary edema (14.5 ± 5.7 ml/kg
versus 9.1 ± 2.7 ml/kg; P = 0.015) (Figure 1D) were ob-
served only for the LVEF <40% group.
In both groups, these hemodynamic variables gradually
and significantly recovered close to each normal range
(multivariate ANOVA for within-group time effect;
P < 0.0001). A statistically significant difference between
the groups was detected only by CFI (multivariate ANOVA
for between-groups over time effect; P < 0.0001). The CFI
between days 0 and 7 was significantly lower in patients
with LV dysfunction (LVEF <40%) than in patients with
LVEF ≥40% (P < 0.05). No statistically significant group
differences were observed for HR, MAP, CVP or SVRI
throughout the study period (see Additional file 2).rrhage patients with versus without left ventricular
LVEF <40% (n = 20) P-value











1.1 (0.2 to 1.9) 0.08
0.16 (0.09 to 0.33) 0.08
0.94 (0.39 to 1.52) 0.15
115 (42 to 192) 0.12
33 (28 to 37) 0.024*
4 (20%) 0.21
10 (50%) 0.011*
ederation of Neurological Surgeons. Numerical variables are presented as
age). Numerical variables were analyzed by Mann–Whitney U test or unpaired
*Significant P-values.
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Figure 1 Changes in hemodynamic parameters over 14 days in 46 subarachnoid hemorrhage patients with Takotsubo cardiomyopathy.
Cardiac function index (CFI) (A), cardiac index (CI) (B), global end-diastolic volume index (GEDI) (C) and extravascular lung water index (ELWI) (D) in
patients with (●) or without (○) left ventricular (LV) dysfunction. Data were obtained from a total of 1,330 PiCCO™ measurements. Averaged data
collected every 12 hours (twice a day) are presented. *P < 0.05 for left ventricular ejection fraction (LVEF) ≥40% versus LVEF <40% at the same time
point. SAH: Subarachnoid hemorrhage.
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dysfunction
LV dysfunction was defined by echocardiograms per-
formed simultaneously with the PiCCO™ measurements
(N = 870 data pairs). The transpulmonary thermodilution-
derived CFI correlated significantly with echocardio-
graphic LVEF (r = 0.82; P < 0.0001) (Figure 2A). To assess
the ability of CFI to detect LVEF <40% in patients with
TCM, ROC curves were generated using values averaged
across all the measurements (Figure 2B). The AUC
(±standard error) was 0.85 ± 0.02 (P < 0.001). A CFI
value <4.2 min−1 had a sensitivity of 82% and specificity
of 84% for detecting LVEF <40%.
We further analyzed whether CFI was useful for
estimating cardiac function during hypervolemia or
hyperdynamic therapy for treating DCI in 25 patients
(Figure 3). CFI was not affected by mild hypervolemia
(change in GEDI = 9 ± 2% from baseline; P < 0.01) or a
slight increase in CI (change in CI = 5 ± 2% from base-
line; P < 0.05) induced by 500 ml of 6% hydroxyethyl
starch (10 ml/kg/hr). In contrast, hyperdynamic therapy
with an incremental dose (3 μg/kg/min) of dobutamine
(maximum dose = 9 ± 3 μg/kg/min) resulted in a change
in CFI of 17 ± 9% after each dose increment (P < 0.05),
with an overall clinical response rate of 52%.Impact of real-time cardiac function index values on clinical
outcomes
Subgroup analysis of clinical outcomes showed that
patients with LVEF <40% had a longer duration of low
CFI <4.2 min−1 (corresponding to predicted LVEF <40%,
defined by at least one CFI <4.2 min−1 over 24 hours)
(mean difference of 4 days; P = 0.0001) and greater inci-
dence of pulmonary edema after day 4 (55% versus 19%;
P = 0.013) than patients with LVEF ≥40%, resulting in a
longer ICU stay (mean difference of 2 days; P = 0.02)
and poorer functional outcome at 3 months (mRS
score of 4 to 6 = 70% versus 31%; P = 0.009) (Table 2).
There were no significant differences between the two
groups with regard to fluid or blood biochemical parame-
ters, rate of DCI or rate of therapy-related pulmonary
edema.
Multivariate logistic regression analysis including sig-
nificant factors associated with DCI (WFNS grades IV
and V, duration of low CFI and coexisting pulmonary
edema) and functional outcomes (WFNS grades IV and V,
prevalence of DCI, duration of low CFI, coexisting
pulmonary edema and length of ICU stay) on univariate
analysis (see Additional files 3 and 4) showed that dur-
ation of low CFI (<4.2 min−1) was independently associ-



















Figure 2 Relationship between cardiac function index and left ventricular ejection fraction in 46 subarachnoid hemorrhage patients
with Takotsubo cardiomyopathy. (A) Three-dimensional regression data plot showing the relationship between cardiac function index (CFI)
and left ventricular ejection fraction (LVEF) and time duration (days after subarachnoid hemorrhage (SAH) onset). Correlation between CFI and
LVEF was analyzed by mixed-effects logistic regression (among subjects, groups, time duration). (B) Receiver operating characteristic curves
constructed based on the sensitivity and specificity of the CFI for identifying LVEF <40%. Data were obtained from a simultaneous measurement
of CFI and LVEF using the PiCCO™ device and echocardiograms, respectively (N = 870 data pairs).
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tional outcome on mRS score of 4 to 6 (OR = 1.87, 95%
confidence interval = 1.06 to 3.29; P = 0.02) (Table 3).
Coexisting pulmonary edema (ELWI >14 ml/kg) also
increased the risk of poor functional outcome at
3 months (OR = 2.10, 95% confidence interval = 1.11 to

























Figure 3 Changes in cardiac function index during volume
expansion and hyperdynamic therapy for delayed cerebral
ischemia–related neurological deterioration in 25 subarachnoid
hemorrhage patients with Takotsubo cardiomyopathy. Graph
shows changes in cardiac index (CI), global end-diastolic volume index
(GEDI) and cardiac function index (CFI) during volume expansion with
500 ml of 6% hydroxyethyl starch (HES) (n = 112) or hyperdynamic
therapy with dobutamine (DOB) (n = 55). Data were collected before
and after each challenge (a 500 ml infusion of HES or an incremental
infusion (3 μg/kg/min) of DOB, sampled in situations without
coadministration) between days 4 and 14. *P< 0.05, **P< 0.01 compared
with baseline before each challenge (% change).Discussion
Our present detailed analysis of hemodynamic parame-
ters monitored using an advanced transpulmonary ther-
modilution technique with the PiCCO™ system provides
new evidence regarding cardiac function and volumetric
changes in patients with SAH complicated by TCM.
This study shows that CFI measured by transpulmonary
thermodilution provides a reliable real-time estimation
of LV systolic function in patients with TCM. CFI in our
patients behaved as an index of LV systolic function
[7,13] in that (1) it had significant correlation with the
echocardiographic LVEF, which is considered the gold
standard for estimating LV systolic function, and reliably
tracked treatment-induced changes in LVEF; and (2) it
did not change with fluid loading, but increased after
administration of an inotropic agent for hyperdynamic
therapy. Furthermore, CFI was sensitive for detecting
LVEF <40%, which is the point at which inotropic support
should be considered [14,27].
Several comorbid risk factors predictive of SAH-
induced TCM and neurogenic pulmonary edema may
operate via increased catecholamines [30,31]. Unfortu-
nately, differences in the levels of circulating catechol-
amines or other biochemical and/or hemodynamic markers
related to stress and fluid regulation did not have a major
impact on outcomes of patients with TCM with or without
LV dysfunction. The results of a recent multicenter cohort
study suggest that low CI, decreased GEDI or increased
systemic vascular resistance (that is, afterload mismatch) at
an early stage may be associated with DCI in patients with
Table 2 Variables associated with left ventricular dysfunction in subarachnoid hemorrhage patients with Takotsubo
cardiomyopathy on univariate analysisa
Variable LVEF ≥40% (n = 26) LVEF <40% (n = 20) P-value
Daily fluid intake, ml 3,182 ± 564 2,976 ± 569 0.18
Fluid output, ml 2,939 ± 446 2,782 ± 541 0.21
Fluid balance, ml 282 ± 163 166 ± 108 0.09
Plasma biochemical markers (peak levels)
Cardiac troponin T, ng/ml 1.1 (0.1 to 1.4) 2.0 (0.2 to 4.0) 0.17
Adrenaline, ng/ml 0.09 (0.03 to 0.14) 0.13 (0.04 to 0.20) 0.10
Noradrenaline, ng/ml 0.59 (0.26 to 0.76) 0.98 (0.39 to 1.66) 0.11
Brain natriuretic peptide, pg/ml 80 (21 to 132) 122 (65 to 191) 0.06
Duration of low CFI, days 2 (0 to 3) 6 (4 to 7) 0.0001*
Pulmonary edema after day 4 5 (19%) 11 (55%) 0.013*
Prevalence of DCI 5 (19%) 10 (50%) 0.029*
New or worsened pulmonary edema 2 (8%) 4 (20%) 0.22
Length of ICU stay, days 13 (10 to 14) 15 (14 to 16) 0.02*
mRS score at 3 months
0 to 3 18 (69%) 6 (30%) 0.009*
4 to 6 8 (31%) 14 (70%)
aCFI: Cardiac function index; DCI: Delayed cerebral ischemia; LVEF: Left ventricular ejection fraction. Numerical variables are presented as median (interquartile
range) or mean ± standard deviation. Categorical variables are expressed as counts (percentage). Numerical variables were analyzed by Mann–Whitney U test or
unpaired Student t-test. Categorical variables were analyzed by χ2 test or Fisher’s exact test. Pulmonary edema was defined as ELWI >14 ml/kg based on the
PiCCO™ measurements. Duration of low CFI was defined by at least one CFI <4.2 min−1 (corresponding to predicted LVEF <40%) over 24 hours.
*Significant P-values.
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in patients with TCM are still unclear. Our results suggest
that TCM-related low CFI (<4.2 min−1) lasting 4 days or
more should alert the physician that LV contraction is prob-
ably impaired and that there is an increased risk of DCI
and poor functional outcome. Persistent LV dysfunction
has also been reported to be associated with pulmonary
edema [33], indicating that early assessment of ELWI and
other clinical and radiological data is useful for earlyTable 3 Variables associated with delayed cerebral ischemia a
patients with Takotsubo cardiomyopathy on multivariate ana
Covariates
DCI
WFNS grade IV or V
Duration of low CFI, days
Coexist pulmonary edema (ELWI >14 ml/kg) after day 4
Poor functional outcome at 3-month follow-up
WFNS grade IV or V
DCI
Duration of low CFI, days
Pulmonary edema after day 4
Length of ICU stay, days
aCFI: Cardiac function index; DCI: Delayed cerebral ischemia; ELWI: Extravascular lun
functional outcome was defined as modified Rankin Scale scores of 4 to 6. Pulmonary
Duration of low CFI was defined by at least one CFI <4.2 min−1 (corresponding to preddetection of pulmonary edema and the need for detailed
examination (such as differentiating between hydrostatic
and permeability edema to evaluate acute lung injury and/
or acute respiratory distress syndrome) [23,34,35].
Our data demonstrate that duration of LV dysfunction
(CFI <4.2 min−1 to predict LVEF <40% with sensitivity of
82% and specificity of 84%) and concurrent pulmonary
edema during DCI risk period (days 4 to 14 after SAH)
are associated with prognosis in patients with post-SAHnd functional outcome in 46 subarachnoid hemorrhage
lysisa
Odds ratio (95% confidence interval) P-value
1.64 (0.07 – 5.87) 0.70
2.14 (1.33 – 2.84) 0.004*
1.66 (0.32 – 2.21) 0.36
1.17 (0.46 – 3.76) 0.20
1.68 (0.07 – 7.29) 0.39
1.87 (1.06 – 3.29) 0.02*
2.10 (1.11 – 3.97) 0.04*
1.93 (0.54 – 1.41) 0.59
g water index; WFNS: World Federation of Neurological Surgeons. Poor
edema was defined as ELWI >14 ml/kg based on the PiCCO™ measurements.
icted LVEF <40%) over 24 hours. *Significant P-values.
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complication of SAH and is often referred to as neu-
rogenic stunned myocardium [33,36]. The results of a
recent analysis of pooled data suggest that TCM and
neurogenic stunned myocardium, regardless of whether
it has regional wall motion abnormalities and elevation
of cardiac enzyme levels, are likely to have common
underlying mechanisms and pathological processes indu-
cing cardiomyopathy [33]. On the other hand, a clinical
entity with milder forms of TCM that do not progress to
LV dysfunction [36] and less prevalence of pulmonary
edema in TCM without LV dysfunction [15,33] has also
been described [36]. These data all highlight the import-
ance of real-time CFI and ELWI monitoring with trans-
pulmonary thermodilution, particularly in postoperative
SAH patients with TCM, at least during the DCI risk
period.
Although we selected postoperative patients with post-
SAH TCM from our prospective cohort of consecutive
SAH patients, this study is limited by its relatively small
sample size and retrospective nature. The study is also
limited by selection bias because it included only patients
who survived long enough to undergo aneurysm coiling
or clipping. The prevalence of TCM in our patients was
comparable with previously reported data (4% to 15%)
[4,15,37]. This study has the advantage of including the
largest reported number of patients with post-SAH TCM
who were successfully monitored for cardiac performance
and volume status for approximately 14 days. The findings
of this two-center study should be validated by larger co-
hort trials. As use of catecholamines for the treatment
of DCI in patients with TCM is still controversial
[5,38,39], future studies should also be focused on es-
tablishing optimal methods of fluid management in
these patients.
Conclusions
The results of this study suggest that prolonged cardiac
dysfunction and concurrent pulmonary edema contribute
to poor functional outcome in SAH patients with TCM.
Serial measurements of transpulmonary thermodilution-
derived CFI and ELWI may provide an easy bedside
method of estimating changes in LV systolic function and
EVLW and predicting clinical outcome.
Key messages
 The incidence of TCM in treatable SAH
patients was 8%, and half of them had concurrent
pulmonary edema.
 Prolonged cardiac dysfunction and pulmonary
edema associated with TCM increased the risk of
DCI, contributing to poor functional outcome in
SAH patients. Serial measurement of CFI and ELWI by
transpulmonary thermodilution may provide an
easy bedside method of detecting early changes in
TCM-induced cardiopulmonary function to direct
proper post-SAH treatment.Additional files
Additional file 1: Detailed description of general managements and
PiCCO™ measurements.
Additional file 2: Changes in hemodynamic parameters over
14 days in 46 SAH patients with TCM. (A) Heart rate (HR), (B) Mean
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(twice a day) have been presented. *P < 0.05 for LVEF ≥40% versus
LVEF <40% at the same time point.
Additional file 3: Univariate analysis of DCI in 46 SAH patients
with TCM.
Additional file 4: Univariate analysis of functional outcome at
3-month follow-up in 46 SAH patients with TCM.
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